COVID-19 vaccine development: AMA news

AMA news and media coverage

The COVID-19 pandemic has accelerated the development and manufacturing of COVID-19 vaccines with recognition that safe and effective vaccine will be essential to reducing morbidity and mortality, and preventing future outbreaks. You can stay up to speed on the AMA’s COVID-19 advocacy efforts and track the fast-moving pandemic with the AMA's COVID-19 resource center, which offers a library of the most up-to-date resources from JAMA Network™, the CDC, and the World Health Organization.

News highlights

- New CDC tools aim to ease COVID-19 vaccine hunt
- How CPT codes are keeping pace with COVID-19 vaccine development
- Which COVID-19 vaccine should I get? What to tell your patients
- 8 coronavirus tips that doctors wish patients would follow
- J&J vaccine and brain blood clots: What physicians should know
- What doctors wish patients knew about life after vaccination

Media coverage

- Statement on ACIP recommendation for Pfizer COVID-19 vaccine booster: The Advisory Committee on Immunization Practices (ACIP) gave a recommendation for individuals 65 years of age and older, long-term care facility residents, persons aged 50–64 with underlying medical conditions and individual risk-benefit analysis for those aged 18–49 with underlying medical conditions to receive a booster dose of the Pfizer-BioNTech COVID-19 vaccine.
- AMA statement on recommendation for Moderna COVID-19 vaccine in U.S.: The recommendation approved by the CDC Director for the use of the Moderna COVID-19 vaccine in the U.S. population is another major step toward vaccinating millions of people across the country.
- AMA announces additional CPT codes for COVID-19 vaccines: The Current Procedural Terminology (CPT®) code set is being updated by the CPT Editorial Panel to include immunization and administration codes that are unique to the COVID-19 vaccine under development by AstraZeneca and University of Oxford.
AMA statement on FDA authorization of first COVID-19 vaccine: The decision by the FDA to grant an Emergency Use Authorization (EUA) for the first COVID-19 vaccine developed by is a monumental milestone.

AMA, AHA, ANA back science-based COVID-19 vaccine process, urge vigilance: As COVID-19 vaccine development continues to progress, leading U.S. medical, nursing and health organizations affirmed their commitment to ensuring COVID-19 vaccines are evaluated and ultimately authorized.

AMA statement on COVID-19 vaccine allocation recommendations: The AMA commends the Advisory Committee on Immunization Practices (ACIP) for their efforts to ensure equitable allocation of COVID-19 vaccines as soon as they become available.

AMA policy aimed at combatting misinformation about COVID-19 vaccines: With misinformation about the COVID-19 vaccine development process circulating widely, physicians at the Special Meeting of the AMA House of Delegates adopted policy aimed at educating physicians on speaking with patients about COVID-19 vaccination.

AMA statement on framework for equitable COVID-19 vaccine allocation: The AMA applauds the National Academy of Medicine’s Committee on Equitable Allocation of Vaccine for the Novel Coronavirus work to develop the framework for equitable allocation of COVID-19 vaccine.

AMA strongly urges FDA transparency in COVID-19 vaccine development: With COVID-19 vaccine development moving at a rapid pace, the AMA is urging the U.S. Food and Drug Administration (FDA) to work more closely with the physician community to develop a plan for further education and transparency surrounding COVID-19 vaccine candidates.